Pay in 4 interest-free payments of $6.54 Learn more
Ships within 48 hours · Estimated delivery Aug 6 - Aug 11
This approval, based on the positive results from the SURMOUNT-CN clinical trial, makes tirzepatide the first dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist approved for obesity treatment in China, which is expected to enhance its market positioning in the country, says GlobalData
They also explored the biochemical alterations underlying metabolic changes in the participants
Yes, but the waiting period is typically longer, usually twelve to sixteen weeks, to allow adequate surgical healing
Patients should contact their GP immediately if they experience severe abdominal pain, persistent vomiting, signs of dehydration, symptoms of hypoglycaemia (trembling, sweating, confusion), or any concerning changes in mood or eating behaviours whilst taking this medication
Weight loss is a multifaceted outcome influenced by diet, physical activity, sleep, stress, appetite, and adherence over time
